Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the ...

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

Researchers said a better understanding of barriers to bone health in hemophilia and VWD is needed, and guidelines should be ...

The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...

Alhemo prophylaxis is linked to better quality of life and a lower treatment burden for hemophilia patients without ...

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.

Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII (FVIII) or IX (FIX), respectively. Patients with these hemophilias are ...

Opens in a new tab or window The FDA approved fitusiran (Qfitlia) as prophylaxis to prevent or reduce bleeding episodes in adults and children ages 12 years and up with hemophilia A or B ...